Inclusion Criteria

- INCLUSION CRITERIA:

- Histologically or cytologically confirmed locally advanced pancreatic adenocarcinoma
or clinical and radiographic evidence of pancreatic cancer

Note: Patients with a limited disease burden outside the pancreas, who have undergone
systemic chemotherapy for metastatic disease and have achieved a complete response on the
metastatic lesions of greater than or equal to 6 months, and have no evidence of disease
outside the pancreas at time of enrollment, are eligible.

- Disease must be evaluable

- Disease should be deemed unresectable by the MD Anderson criteria

- Patients may be chemo naive or have received prior chemotherapy (including
Gemcitabine) and/or radiation

- Greater than or equal to 18 years of age

- Must be able to understand and sign the Informed Consent Document

- Clinical performance status of ECOG less than or equal to 2

- Life expectancy of greater than three months

- Patients of both genders must be willing to practice birth control during and for
four months after receiving chemotherapy

- Hematology:

- Absolute neutrophil count greater than 1300/mm(3) without the support of
Filgrastim.

- Platelet count greater than 75,000/mm(3).

- Hemoglobin greater than 8.0 g/dl.

- Chemistry:

- Serum ALT/AST less or equal to 3 times the upper limit of normal, unless patient
carries a biliary stent. For these patients, to account for asymptomatic,
transient elevations in transaminases ('transaminitis'), serum ALT/AST may be
less than or equal to 5 tims the upper limit of normal provided all other
eligibility parameters are met.

- Serum creatinine less than or equal to 1.8 mg/dl unless the measured creatinine
clearance is greater than 60 mL/min/1.73 m(2)

- Total bilirubin less than or equal to 2 mg/dl,

- PT within 2 seconds of the upper limit of normal or INR less than or equal to
1.8

- No history of prior/other malignancies within the 2 years prior to enrollment with
the exception of basal cell carcinoma

EXCLUSION CRITERIA:

- Metastatic disease including malignant ascities

- Women of child-bearing potential who are pregnant or breastfeeding because of the
potentially dangerous effects of the chemotherapy on the fetus or infant.

- Active systemic infections, coagulation disorders or other major medical illnesses of
the cardiovascular, respiratory or immune system, myocardial infarction, heart
failure

- Childs B or C cirrhosis or with evidence of severe portal hypertension by history,
endoscopy, or radiologic studies

- Weight less than 40 kg

- Significant ascites, greater than 1000cc in the absence of peritoneal disease

- Concomitant medical problems that would place the patient at an unacceptable risk for
the procedure

- Need for concurrent chemotherapy

- Discretion of the PI